Scott Gottlieb Confirmed as FDA Commissioner
Yesterday Scott Gottlieb, M.D., President Trump’s nominee who has been criticized for his ties to the pharmaceutical industry, was confirmed by the Senate to lead FDA as its next commissioner. The vote was 57 to 42.
“Dr. Gottlieb brings considerable experience to the FDA. His background will be crucial for keeping the FDA as the gold standard for safe treatments while advancing new, innovative solutions to the many public health challenges our nation faces. I am confident Dr. Gottlieb will make decisions that reduce regulatory burdens while protecting public health.” – HHS Secretary Tom Price, M.D.
AdvaMed praised the confirmation, citing Gottlieb’s qualifications due to experience at FDA and CMS. The association will work with the new commissioner on key issues, including improving the FDA review process, reauthorization of MDUFMA and implementing the 21st Century Cures Act. “Dr. Gottlieb recognizes the crucial role of medical technology in solving some of our nation’s most daunting health care challenges and the importance of a strong, efficient and predictable FDA in ensuring continued patient access to safe and effective medical innovations,” stated President and CEO Scott Whitaker.
Related Articles
-
The MDDT program was developed in collaboration with the National Institutes of Health’s (NIH’s) National Institute of Drug Abuse (NIDA), National Institute of Dental Craniofacial Research (NIDCR) and National Cancer Institute (NCI) as a way for the FDA to qualify…
-
The new guidance is intended to establish confidence in automation used for production or quality assurance systems and describe various methods and testing activities that may be applied to establish computer software assurance and meet regulatory software validation requirements.
-
Califf faced strong opposition but was confirmed in a very close vote.
-
“Content of Human Factors Information in Device Marketing Submissions” and “Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers” are now open for comment.
